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Background: The metabolic syndrome is defined as an assemblage of risk factors for cardiovascular diseases, and
menopause is associated with an increase in metabolic syndrome prevalence. The aim of this study was to assess
the prevalence of metabolic syndrome and its components among postmenopausal women in Tehran, Iran.
Methods: In this cross-sectional study in menopause clinic in Tehran, 118 postmenopausal women were
investigated. We used the adult treatment panel 3 (ATP3) criteria to classify subjects as having metabolic syndrome.
Results: Total prevalence of metabolic syndrome among our subjects was 30.1%. Waist circumference, HDL-
cholesterol, fasting blood glucose, diastolic blood pressure ,Systolic blood pressure, and triglyceride were
significantly higher among women with metabolic syndrome (P-value<0.05). Our study shows high abdominal
obesity and hypertension are the most prevalent components of metabolic syndrome. 15%, 13.3% and 1.8% of
subjects had three, four and five criteria for metabolic syndrome, respectively. There was a significant relationship
between number of components of metabolic syndrome and waist circumference.
Conclusions: Our study shows that postmenopausal status is associated with an increased risk of metabolic
syndrome. Therefore, to prevent cardiovascular disease there is a need to evaluate metabolic syndrome and its
components from the time of the menopause.
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Metabolic syndrome is an assemblage of several factors
including hypertension, dyslipidemia, insulin resistance,
obesity and glucose intolerance that increase subjects'
risk to develop cardiovascular disease (CVD) and type 2
diabetes [1,2]. Diagnostic criteria for metabolic syn-
drome has been defined by the national cholesterol edu-
cation program adult treatment panel ΙΠ (ATP ΙΠ),
which is easily used for classifying patients [3]. It's esti-
mated that almost 20-30% of the middle-aged popula-
tion are affected by this syndrome [4] varies from 8 to
24% in males [5,6] and from 7 to 46% in females [7,8].
Many cross-sectional studies have shown an increased
risk of metabolic syndrome in postmenopausal women
which varies from 32.6% to 41.5% [9-11]. Some studies
show an increasing prevalence of metabolic syndrome in
developing countries and Asia [12] and an estimated
prevalence in Iran from 35-58% [13,14]. As there is not
enough data on the prevalence of metabolic syndrome* Correspondence: asadim@tums.ac.ir
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distribution, and reproduction in any mediumamong postmenopausal women in Tehran referral hospi-
tals, we decided to establish a study in menopause clinic
of Tehran women general hospital to determine the
prevalence of metabolic syndrome and its components
in postmenopausal women.
Methods
This cross-sectional study was performed in menopause
clinic of Tehran women general hospital. The study was
performed on 118 postmenopausal women from January
2011 to January 2012 in the menopause clinic. Meno-
pause was defined as at least 12 consecutive months of
amenorrhea with no other medical cause. Exclusion cri-
teria were considered as surgical menopause and chemo
radiotherapy. No other conditions or disease have been
considered. The women mostly were visited in the clinic
because of hot flashes, mood swing, vaginal dryness,
sleep disturbances, night sweat, forgetfulness, urinary
symptoms, pain with intercourse, palpitations, anxiety,
joint and muscle pain, depression and irritability.
A questionnaire was completed for each patient in-
cluding demographic information, menopausal status,
medical history, reproductive history, drug history,tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Baseline data of postmenopausal women with














0.272 52.56±4.81 53.61±4.51 52.67±5 Age(years)
0.315 47.62±4.31 48.47±3.93 47.66±4.44 Menopausal
age(years)
0.001 88.34±9.20 94.91±8.89 90.45±9.56 WC(cm)
0.042 118.79±18.78 125.91±15.83 120.64±
18.08
SBP(mmHg)
0.003 79.81±11.33 85±7.48 81.06±10.54 DBP(mmHg)
0.001 99.82±30.86 111.20±29.20 103.35±30.35 FBS(mg/dl)
<0.05 124.68±53.50 200.64±103.99 146.92±79.94 TG(mg/dl)
0.571 215.06±39.97 211.08±31.12 213.83±37.16 Total
Cholesterol
(mg/dl)
<0.05 58.20±12.11 47.35±8.22 55.03±12.04 HDL(mg/dl)
0.408 128.94±31.24 124.20±26.14 127.36±29.37 LDL(mg/dl)
*WC: waist circumference, SBP: systolic blood pressure, DBP:diastolic blood
pressure, FBS:fasting blood glucose, TG: triglyceride, HDL:high density
lipoprotein, LDL: low density lipoprotein.
**P-value<0.05 was considered statistically significant.
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An inform consent was signed by each patient in the
clinic. Postmenopausal women were considered to have
metabolic syndrome if they had any three or more of the
following criteria, according to the ATP ΙΠ criteria [2]:
1. Abdominal obesity: waist circumference≥ 88 cm
2. Hypertriglyceridemia: serum TG level ≥ 150 mg/dl
3. Serum HDL: < 50 mg/dl
4. High blood pressure: SBP ≥ 130 mmHg and/or DBP
≥ 85 mmHg or on treatment for hypertension
5. High fasting glucose: serum glucose level > 110 mg/
dl or on treatment for diabetes
Waist circumference was measured at a level midpoint
between the lower rib margin and the top of the iliac
crest. Blood pressure of the patients was measured twice
with a standard barometer in a sitting position, and the
average blood pressure had been documented in the
sheets. All data were analyzed by SPSS version 16 (SPSS
Inc, Chicago, IL, USA). The continuous variables are
reported as Mean ± SD and categorical variables are pre-
sented as percentage. The distribution of continuous
variables was assessed by Kolomogrov-Smirnov test and
it demonstrated a normal distribution. A P-value<0.05
was considered statistically significant.Table 2 Prevalence of metabolic syndrome and the
components of metabolic syndrome in postmenopausal
women
30.1% Metabolic syndrome
64.3% Waist circumference≥88 cm
35.6% Triglyceride≥150 mg/dl
35.6% HDL-cholesterol<50 mg/dl
47.9% Systolic blood pressure≥130 mmHg/diastolic blood pressure≥85
mmHg
29.1% Fasting blood glucose>110 mg/dlResults
A total of 118 postmenopausal women were studied.
Table 1 shows the baseline characteristics of these
women with and without metabolic syndrome. The
mean age of our subjects was 52.67 ± 5 years and the
mean age of menopause was 47.66 ± 4.44 years. Total
prevalence of metabolic syndrome among our subjects
was 30.1%.
Waist circumference, HDL-cholesterol, fasting blood
glucose, diastolic blood pressure ,Systolic blood pressure,
and triglyceride were significantly higher among women
with metabolic syndrome (P-value<0.05). There were no
significant differences in the age, menopausal age, total
cholesterol and LDL-cholesterol. The percentage of fasting
blood sugar>110 mg/dl, high density lipoprotein<50 mg/dl,
Triglyceride≥150 mg/dl, waist circumference≥88 cm, and
systolic blood pressure ≥130 mmHg/diastolic blood pre-
ssure≥85 mmHg were 29.1%, 35.6%, 35.6%, 64.3%, 47.9%
respectively. The percentages of each metabolic syndrome
components are shown in Table 2. Table 3 shows preva-
lence of subjects with criteria of metabolic syndrome which
shows 15%, 13.3% and 1.8% had three, four and five criteria
for metabolic syndrome respectively. There was a signifi-
cant relevancy between number of metabolic syndrome
components and increasing waist circumference (P-value:
0.001) with a statistically significant linearity (<0.05).Discussion
In our study the overall prevalence of metabolic syn-
drome was 30.1% among postmenopausal women. Other
studies report a prevalence of metabolic syndrome near
to our results. A cross-sectional study in Gorgan prov-
ince in Iran shows a prevalence of 31% [15] which was
similar to our findings. Other Studies in Austria, China,
Germany, Iran and Canada showed a prevalence of
32.6%, 37.34%, 36.1%, 31% and 29.6% respectively [9,16-19]
in an agreement with our finding. Although there was a dis-
agreement between our study and some other studies done
in Iran, western India, Argentina and Ecuador with a preva-
lence of 69%, 55%, 22% and 41.5% respectively [20-23].
These differences in prevalence of metabolic syndrome in
different studies can be due to different investigation met-
hods of the syndrome (different investigation criteria),
Table 3 Number of metabolic syndrome components versus waist circumference
P-value Five Four Three Two One None Metabolic syndrome components
0.001 105.50±2.12 94.26±6.80 94.23±10.37 89.94±9.29 89.03±10.01 82.64±4.32 Mean±SD Waist circumference
1.8 13.3 15 33.6 23.9 12.4 Percent
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tors and lifestyle. In our study, we found that waist circum-
ference, systolic blood pressure, diastolic blood pressure,
fasting blood sugar, triglyceride and HDL levels were sig-
nificantly higher among postmenopausal women with
metabolic syndrome in comparison to postmenopausal
women without metabolic syndrome. The most prevalent
component of metabolic syndrome was abdominal obesity
with a frequency of 64.3%, which is in agreement with stud-
ies in north east of Iran [24], Babol [18] and Argentina [25]
about the most prevalent component of metabolic syn-
drome among postmenopausal women with metabolic syn-
drome. This is not exactly similar to the findings of other
studies in Ecuador [23] with high TG level and in Korea
[26], Brazil [25] and Iran [15] with low HDL-cholesterol
level reported as the most prevalent component of meta-
bolic syndrome. These differences may be due to genetic,
ethnic and lifestyle differences in these countries. Table 4
shows the prevalence of metabolic syndrome and its com-
ponents done in different studies over the world.
We found a statistically significant relationship be-
tween waist circumference and number of metabolic
syndrome components, which was in agreement with
study done by Marjani et al. in Gorgan [15]. Abdominal
obesity is a risk factor for cardiovascular disorders
[28,29] and can cause metabolism abnormality and
threaten human’s health [30]. Therefore, it is necessary
to reduce this risk among postmenopausal women with
metabolic syndrome by changing the lifestyle leading
to weight loss by a healthy diet and frequent physical
activity.
In our study we found that both systolic and diastolic
blood pressure was higher among post menopausal
women with metabolic syndrome specially DBP. Marjani
et al. also showed a significantly high diastolic blood
pressure among postmenopausal women in Gorgan [15].Table 4 Prevalence of metabolic syndrome and its componen
Study Number Metabolic syndrome Htn
Iran Gorgan 100 31% 16%
North East 160 20.62% 3.12
Babol 984 31% 12.1
Tehran 940 53.5% 16.5
Brazil 323 44.4% 65%
Argentina 124 22% 8%
Ecuador 325 41.5% 65.9
Korea 778 54.6% 63.6This may suggest us that diastolic blood pressure is a
risk factor for CHD in postmenopausal women with
metabolic syndrome that should be considered.
A significant difference of impaired fasting glucose
was found among postmenopausal women with and
without metabolic syndrome in our study. Walton and
colleges also report an increase in FBS among postme-
nopausal women with metabolic syndrome [31].
Finally, Our findings show low HDL and high TG
levels in postmenopausal women with metabolic syn-
drome, which is in agreement with findings in studies
done by Marjani et al. [15] in Iran and Figueiredo Neto
et al. [25] in Brazil. There are controversial findings
about menopausal effect on HDL [32,33] and TG levels
[32,34]. Our findings about high prevalence of dyslipide-
mia among postmenopausal women with metabolic syn-
drome indicate a need to treat metabolic syndrome in
postmenopausal women as a target for reducing cardio-
vascular risks with an special effort on lifestyle changing
and daily diets.
A limitation of this study was the small population
studied, done as a cross-sectional study which may limit
generalization of this study to all parts of Iran. There is
a need of further studies to confirm the results found
and, then, take actions to prevent metabolic syndrome
in postmenopausal women.
Conclusion
Our study has shown a high prevalence of metabolic
syndrome among postmenopausal women referring to
menopause clinic in Tehran women general hospital that
abdominal obesity and hypertension were the most
prevalent components of metabolic syndrome among
these patients. These components can lead to an in-
crease in cardiovascular diseases. Interventions are
needed to modify these risk factors such as abdominalts in different studies [15,18,22-27]
High TG Impaired FBS Low HDL High WC
16% 17% 30% 29%
% 20% 14.30% 29.37% 34.37%
% 41.5% 12.1% 48.6% 76.6%
% 104.4% 66.2% 12.5% 9.8%
12.4% 11.8% 79.6% 50.9%
8% 2% 10% 13%
% 83% 29.6% 80% 83.7%
% 39.3% 26% 69.8% 67.1%
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ance and reduce the risk of cardiovascular events.
Therefore, it is important to have more efforts for lipid
screening and educational programs to improve women’s
knowledge about a healthy lifestyle.
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